Otte Christian, Wingenfeld Katja, Kuehl Linn K, Richter Steffen, Regen Francesca, Piber Dominique, Hinkelmann Kim
Department of Psychiatry and Psychotherapy, Charité University Medical Center, Campus Benjamin Franklin, Berlin, Germany.
Department of Psychiatry and Psychotherapy, Charité University Medical Center, Campus Benjamin Franklin, Berlin, Germany.
J Psychiatr Res. 2015 Oct;69:120-5. doi: 10.1016/j.jpsychires.2015.08.001. Epub 2015 Aug 4.
Memory and executive function are often impaired in older adults with major depression. Mineralocorticoid receptors (MR) are abundantly expressed in the hippocampus and in the prefrontal cortex, brain areas critical for memory and executive function. In both aging and depression, MR expression in the brain is reduced. Therefore, diminished MR function could contribute to impaired cognition in older adults with depression and might be a promising target for pharmacological intervention. Twenty-three older adults with major depression (mean age 61.6 yrs ± 8.1, n = 13 women) without medication and 24 age-, sex- and education-matched healthy participants received the MR-agonist fludrocortisone (0.4 mg) or placebo in a randomized, double-blind, within-subject cross-over design. We measured psychomotor speed, executive function, verbal learning and memory, and visuospatial memory. Compared to controls, depressed patients performed worse in psychomotor speed (group effect p = 0.01), executive function (group effect p < 0.01), verbal learning (group effect p = 0.02), and verbal memory (group effect p < 0.01) but not in visuospatial memory. There were no significant treatment effects. However, we found a group × treatment interaction in verbal learning (p = 0.04) and visuospatial memory (p = 0.02) indicating that depressed patients performed worse after fludrocortisone whereas controls performed better after fludrocortisone. Our data suggest that -in contrast to younger depressed patients-older adults with depression do not benefit from MR stimulation but deteriorate in cognitive function.
患有重度抑郁症的老年人的记忆和执行功能常常受损。盐皮质激素受体(MR)在海马体和前额叶皮质中大量表达,而这两个脑区对记忆和执行功能至关重要。在衰老和抑郁症中,大脑中的MR表达都会降低。因此,MR功能减弱可能导致患有抑郁症的老年人认知功能受损,并且可能是药物干预的一个有前景的靶点。23名未服用药物的患有重度抑郁症的老年人(平均年龄61.6岁±8.1岁,n = 13名女性)以及24名年龄、性别和教育程度相匹配的健康参与者,在一项随机、双盲、受试者内交叉设计中接受了MR激动剂氟氢可的松(0.4毫克)或安慰剂治疗。我们测量了心理运动速度、执行功能、言语学习和记忆以及视觉空间记忆。与对照组相比,抑郁症患者在心理运动速度(组效应p = 0.01)、执行功能(组效应p < 0.01)、言语学习(组效应p = 0.02)和言语记忆(组效应p < 0.01)方面表现更差,但在视觉空间记忆方面没有差异。没有显著的治疗效果。然而,我们在言语学习(p = 0.04)和视觉空间记忆(p = 0.02)中发现了组×治疗交互作用,表明抑郁症患者在服用氟氢可的松后表现更差,而对照组在服用氟氢可的松后表现更好。我们的数据表明,与年轻的抑郁症患者不同,患有抑郁症的老年人无法从MR刺激中获益,反而认知功能会恶化。